| Name | Indisulam |
| Description | Indisulam (E 7070) is a carbonic anhydrase inhibitor and antitumor CDK inhibitor that targets the G1 phase of the cell cycle by depleting cyclin E, inducing p53 and p21, and inhibiting CDK2, thereby causing a blockade in the G1/S transition. |
| In vitro | In vitro, indisulam has antiproliferative effects on a wide range of human tumor lines with HCT116 colorectal being the most sensitive and NCI-H596 non-small cell lung cancer (NSCLC) the most resistant (IC50s = 0.11 and 94 μg/ml, respectively). It increases the number of P388 murine leukemia cells in the G1 phase of the cell cycle in a dose-dependent manner and exerts time-dependent cytotoxicity against HCT116 cells. |
| In vivo | In vivo, indisulam suppresses tumor growth and decreases tumor volume in murine HCT116, SW620, and HCT15 colorectal and LX-1 and PC9 lung cancer xenograft models. Indisulam induces proteasomal degradation of RNA binding motif protein 39 (RBM39) through association with the CUL4-DCAF15 E3 ubiquitin ligase in vitro.It is also an inhibitor of carbonic anhydrase in H. pylori (Ki = 310-562 nM). Formulations containing indisulam are under Clinicalal investigation for the treatment of solid tumors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 145 mg/mL (375.79 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.18 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Indisulam | E-7070 | E7070 | CDK | CarbonicAnhydrase | Carbonic Anhydrase | Carbonate dehydratase |
| Inhibitors Related | Benzenesulfonamide | Urea | Sodium Dihydrogen Phosphate | 2-Chloropyrazine | Kojic acid | Cyclamic acid sodium | Hydrochlorothiazide | Abemaciclib | Lenalidomide | Palbociclib | Sodium Oxamate | Acesulfame |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
